Low-dose-rate brachytherapy as the sole radiation modality in the management of patients with early-stage breast cancer treated with breast- conserving therapy

Preliminary results of a pilot trial

Frank A. Vicini, Peter Y. Chen, Marta Fraile, Gary S. Gustafson, Gregory K. Edmundson, David A. Jaffray, Pamela Benitez, Jane Pettinga, Beatrice Madrazo, John A. Ingold, Neal S. Goldstein, Richard C. Matter, Alvaro A. Martinez

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Purpose: We present the preliminary findings of our in-house protocol treating the tumor bed alone after lumpectomy with low-dose-rate (LDR) interstitial brachytherapy in selected patients with early-stage breast cancer treated with breast-conserving therapy (BCT). Methods and Materials: Since March 1, 1993, 60 women with early-stage breast cancer were entered into a protocol of tumor bed irradiation only using an interstitial LDR implant with iodine-125. Patients were eligible if the tumor was ≤3 cm, margins were ≤2 mm, there was no extensive intraductal component, the axilla was surgically staged, and a postoperative mammogram was performed. Implants were placed using a standardized template either at the time of reexcision or shortly after lumpectomy. A total of 50 Gy was delivered at 0.52 Gy/h over a period of 96 h to the lumpectomy bed plus a 2-cm margin. Perioperative complications, cosmetic outcome, and local control were assessed. Results: The median follow-up for all patients is 20 months. Three patients experienced minimal perioperative pain that required temporary nonnarcotic analgesics. There have been four postoperative infections which resolved with oral antibiotics. No significant skin reactions related to the implant were noted and no patient experienced impaired would healing. Early cosmetic results reveal minimal changes consisting of transient hyperpigmentation of the skin at the puncture sites and temporary induration in the tumor bed. Good to excellent cosmetic results were noted in all 19 patients followed up a minimum of 24 months posttherapy. To date, 51 women have obtained 6-12- month follow-up mammograms and no recurrences have been noted. All patients currently have no physical signs of recurrence, and no patient has failed regionally or distantly. Conclusion: Treatment of the tumor bed alone with LDR interstitial brachytherapy appears to he well tolerated, and early results are promising. Long-term follow-up of these patients is necessary to establish the equivalence of this treatment approach compared to standard BCT, however.

Original languageEnglish
Pages (from-to)301-310
Number of pages10
JournalInternational Journal of Radiation Oncology Biology Physics
Volume38
Issue number2
DOIs
StatePublished - May 1 1997
Externally publishedYes

Fingerprint

Brachytherapy
breast
therapy
Breast
cancer
Radiation
Breast Neoplasms
dosage
radiation
beds
tumors
Segmental Mastectomy
Cosmetics
interstitials
Therapeutics
Neoplasms
margins
iodine 125
Non-Narcotic Analgesics
Recurrence

Keywords

  • Brachytherapy
  • Breast-conserving therapy
  • Low dose rate

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Low-dose-rate brachytherapy as the sole radiation modality in the management of patients with early-stage breast cancer treated with breast- conserving therapy : Preliminary results of a pilot trial. / Vicini, Frank A.; Chen, Peter Y.; Fraile, Marta; Gustafson, Gary S.; Edmundson, Gregory K.; Jaffray, David A.; Benitez, Pamela; Pettinga, Jane; Madrazo, Beatrice; Ingold, John A.; Goldstein, Neal S.; Matter, Richard C.; Martinez, Alvaro A.

In: International Journal of Radiation Oncology Biology Physics, Vol. 38, No. 2, 01.05.1997, p. 301-310.

Research output: Contribution to journalArticle

Vicini, Frank A. ; Chen, Peter Y. ; Fraile, Marta ; Gustafson, Gary S. ; Edmundson, Gregory K. ; Jaffray, David A. ; Benitez, Pamela ; Pettinga, Jane ; Madrazo, Beatrice ; Ingold, John A. ; Goldstein, Neal S. ; Matter, Richard C. ; Martinez, Alvaro A. / Low-dose-rate brachytherapy as the sole radiation modality in the management of patients with early-stage breast cancer treated with breast- conserving therapy : Preliminary results of a pilot trial. In: International Journal of Radiation Oncology Biology Physics. 1997 ; Vol. 38, No. 2. pp. 301-310.
@article{e31a89d60d12451a8090249b58705ca6,
title = "Low-dose-rate brachytherapy as the sole radiation modality in the management of patients with early-stage breast cancer treated with breast- conserving therapy: Preliminary results of a pilot trial",
abstract = "Purpose: We present the preliminary findings of our in-house protocol treating the tumor bed alone after lumpectomy with low-dose-rate (LDR) interstitial brachytherapy in selected patients with early-stage breast cancer treated with breast-conserving therapy (BCT). Methods and Materials: Since March 1, 1993, 60 women with early-stage breast cancer were entered into a protocol of tumor bed irradiation only using an interstitial LDR implant with iodine-125. Patients were eligible if the tumor was ≤3 cm, margins were ≤2 mm, there was no extensive intraductal component, the axilla was surgically staged, and a postoperative mammogram was performed. Implants were placed using a standardized template either at the time of reexcision or shortly after lumpectomy. A total of 50 Gy was delivered at 0.52 Gy/h over a period of 96 h to the lumpectomy bed plus a 2-cm margin. Perioperative complications, cosmetic outcome, and local control were assessed. Results: The median follow-up for all patients is 20 months. Three patients experienced minimal perioperative pain that required temporary nonnarcotic analgesics. There have been four postoperative infections which resolved with oral antibiotics. No significant skin reactions related to the implant were noted and no patient experienced impaired would healing. Early cosmetic results reveal minimal changes consisting of transient hyperpigmentation of the skin at the puncture sites and temporary induration in the tumor bed. Good to excellent cosmetic results were noted in all 19 patients followed up a minimum of 24 months posttherapy. To date, 51 women have obtained 6-12- month follow-up mammograms and no recurrences have been noted. All patients currently have no physical signs of recurrence, and no patient has failed regionally or distantly. Conclusion: Treatment of the tumor bed alone with LDR interstitial brachytherapy appears to he well tolerated, and early results are promising. Long-term follow-up of these patients is necessary to establish the equivalence of this treatment approach compared to standard BCT, however.",
keywords = "Brachytherapy, Breast-conserving therapy, Low dose rate",
author = "Vicini, {Frank A.} and Chen, {Peter Y.} and Marta Fraile and Gustafson, {Gary S.} and Edmundson, {Gregory K.} and Jaffray, {David A.} and Pamela Benitez and Jane Pettinga and Beatrice Madrazo and Ingold, {John A.} and Goldstein, {Neal S.} and Matter, {Richard C.} and Martinez, {Alvaro A.}",
year = "1997",
month = "5",
day = "1",
doi = "10.1016/S0360-3016(97)00035-7",
language = "English",
volume = "38",
pages = "301--310",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Low-dose-rate brachytherapy as the sole radiation modality in the management of patients with early-stage breast cancer treated with breast- conserving therapy

T2 - Preliminary results of a pilot trial

AU - Vicini, Frank A.

AU - Chen, Peter Y.

AU - Fraile, Marta

AU - Gustafson, Gary S.

AU - Edmundson, Gregory K.

AU - Jaffray, David A.

AU - Benitez, Pamela

AU - Pettinga, Jane

AU - Madrazo, Beatrice

AU - Ingold, John A.

AU - Goldstein, Neal S.

AU - Matter, Richard C.

AU - Martinez, Alvaro A.

PY - 1997/5/1

Y1 - 1997/5/1

N2 - Purpose: We present the preliminary findings of our in-house protocol treating the tumor bed alone after lumpectomy with low-dose-rate (LDR) interstitial brachytherapy in selected patients with early-stage breast cancer treated with breast-conserving therapy (BCT). Methods and Materials: Since March 1, 1993, 60 women with early-stage breast cancer were entered into a protocol of tumor bed irradiation only using an interstitial LDR implant with iodine-125. Patients were eligible if the tumor was ≤3 cm, margins were ≤2 mm, there was no extensive intraductal component, the axilla was surgically staged, and a postoperative mammogram was performed. Implants were placed using a standardized template either at the time of reexcision or shortly after lumpectomy. A total of 50 Gy was delivered at 0.52 Gy/h over a period of 96 h to the lumpectomy bed plus a 2-cm margin. Perioperative complications, cosmetic outcome, and local control were assessed. Results: The median follow-up for all patients is 20 months. Three patients experienced minimal perioperative pain that required temporary nonnarcotic analgesics. There have been four postoperative infections which resolved with oral antibiotics. No significant skin reactions related to the implant were noted and no patient experienced impaired would healing. Early cosmetic results reveal minimal changes consisting of transient hyperpigmentation of the skin at the puncture sites and temporary induration in the tumor bed. Good to excellent cosmetic results were noted in all 19 patients followed up a minimum of 24 months posttherapy. To date, 51 women have obtained 6-12- month follow-up mammograms and no recurrences have been noted. All patients currently have no physical signs of recurrence, and no patient has failed regionally or distantly. Conclusion: Treatment of the tumor bed alone with LDR interstitial brachytherapy appears to he well tolerated, and early results are promising. Long-term follow-up of these patients is necessary to establish the equivalence of this treatment approach compared to standard BCT, however.

AB - Purpose: We present the preliminary findings of our in-house protocol treating the tumor bed alone after lumpectomy with low-dose-rate (LDR) interstitial brachytherapy in selected patients with early-stage breast cancer treated with breast-conserving therapy (BCT). Methods and Materials: Since March 1, 1993, 60 women with early-stage breast cancer were entered into a protocol of tumor bed irradiation only using an interstitial LDR implant with iodine-125. Patients were eligible if the tumor was ≤3 cm, margins were ≤2 mm, there was no extensive intraductal component, the axilla was surgically staged, and a postoperative mammogram was performed. Implants were placed using a standardized template either at the time of reexcision or shortly after lumpectomy. A total of 50 Gy was delivered at 0.52 Gy/h over a period of 96 h to the lumpectomy bed plus a 2-cm margin. Perioperative complications, cosmetic outcome, and local control were assessed. Results: The median follow-up for all patients is 20 months. Three patients experienced minimal perioperative pain that required temporary nonnarcotic analgesics. There have been four postoperative infections which resolved with oral antibiotics. No significant skin reactions related to the implant were noted and no patient experienced impaired would healing. Early cosmetic results reveal minimal changes consisting of transient hyperpigmentation of the skin at the puncture sites and temporary induration in the tumor bed. Good to excellent cosmetic results were noted in all 19 patients followed up a minimum of 24 months posttherapy. To date, 51 women have obtained 6-12- month follow-up mammograms and no recurrences have been noted. All patients currently have no physical signs of recurrence, and no patient has failed regionally or distantly. Conclusion: Treatment of the tumor bed alone with LDR interstitial brachytherapy appears to he well tolerated, and early results are promising. Long-term follow-up of these patients is necessary to establish the equivalence of this treatment approach compared to standard BCT, however.

KW - Brachytherapy

KW - Breast-conserving therapy

KW - Low dose rate

UR - http://www.scopus.com/inward/record.url?scp=0030753802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030753802&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(97)00035-7

DO - 10.1016/S0360-3016(97)00035-7

M3 - Article

VL - 38

SP - 301

EP - 310

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -